T-20 launched in UK

1 September 2003. Related: Antiretrovirals.

Following approval in the EU on 28 May, T-20 (enfuvirtide, Fuzeon), was launched in the UK on 3 July 2003.

It is the first of a new class of entry inhibitors, and results from studies in treatment experienced patients have been closely reported previously in HTB.

Links:

EMEA European Public Assessment Reports
http://www.emea.eu.int/humandocs/Humans/EPAR/fuzeon/fuzeon.htm

Roche press release
http://www.roche.com/med-corp-detail-2003?id=990&media-language=e

Enfuvirtide (T-20): predicting success and modelling survival benefits
http://www.i-base.info/pub/htb/v4/htb4-1/Enfuvirtide.html